Prestige Consumer Healthcare Inc.
NYSE:PBHMedical - Distribution
+$0.23 today
- Market cap
- $2.40B
- Beta
- 0.35
- P/E (TTM)
- 11.6
- EPS (TTM)
- $4.01
Volume 0.62M
Average 0.67M
PBH Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Prestige Consumer Healthcare Inc.NYSE: PBH
Research & Development · Q1 FY2027 · quarter ended Jun 2026
Research & development remains negative
Q1 FY2027 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $0.
Context
- Research & development amounted to 0.0% of revenue in FY2026, unchanged from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2026
- 0 USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 0 | — |
| FY2025 | 2025-03-31 | 0 | — |
| FY2024 | 2024-03-31 | 0 | — |
| FY2023 | 2023-03-31 | 0 | — |
| FY2022 | 2022-03-31 | 0 | — |
Research & Development vs competitors
How PBH compares with its peers on the latest reported figures
- PBH's LTM Jun 2026 research & development of $0 is the 9th highest of the 11 companies compared; the peer median is $91.18M.
- Research & development amounts to 0.0% of revenue for PBH, versus a peer median of 9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $378.58M | -9.4% | +7.3% | 27.9% | |
| LTM Jun 2026 | $236.92M | +3.2% | -8.3% | 52.7% | |
| LTM Sep 2026 | $202.57M | +14.5% | +6.0% | 13.4% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $183.14M | +22.7% | +72.2% | — |
HTFLHeartflow, Inc. Common Stock | LTM Sep 2026 | $96.03M | +64.1% | — | 40.2% |
| LTM Jun 2026 | $86.32M | -2.5% | -2.0% | 4.0% | |
| LTM Mar 2026 | $77.25M | -2.6% | +20.1% | 9.8% | |
| LTM Mar 2026 | $11.48M | -17.7% | -13.7% | 1.9% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
CONConcentra Group Holdings Parent, Inc. | LTM Sep 2026 | $0 | — | — | 0.0% |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding PBH) | $91.18M | +0.3% | +6.0% | 9.8% | |
Competitors are the stored peer set for PBH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 1.09B | 1.13B | 1.13B | 1.14B | 1.09B |
| Cost of Revenue | 466.17M | 502.43M | 500.91M | 503.3M | 514.07M |
| Gross Profit | 620.65M | 625.29M | 624.45M | 634.46M | 574.64M |
| Gross Margin | 57.1% | 55.4% | 55.5% | 55.8% | 52.8% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 264.8M | 252.42M | 259.47M | 263.93M | 265.23M |
| Operating Expenses | 290.73M | 647.71M | 282.02M | 297.69M | 265.23M |
| Depreciation & Amortization | 32.09M | 32.63M | 30.68M | 30.17M | 31.27M |
| EBITDA | 358.84M | 7.87M | 373.86M | 361.99M | 331.11M |
| EBITDA Margin | 33.0% | 0.7% | 33.2% | 31.8% | 30.4% |
| Operating Income | 329.92M | (22.42M) | 342.43M | 336.78M | 309.41M |
| Operating Margin | 30.4% | -2.0% | 30.4% | 29.6% | 28.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 64.29M | 69.16M | 67.16M | 47.63M | 42.34M |
| Other Income / Expenses | (67.46M) | (71.5M) | (66.4M) | (52.59M) | (51.91M) |
| Income Before Tax | 262.46M | (93.92M) | 276.03M | 284.19M | 257.5M |
| Pre-Tax Margin | 24.1% | -8.3% | 24.5% | 25.0% | 23.7% |
| Income Tax Expense | 57.08M | (11.61M) | 66.69M | 69.58M | 67.2M |
| Net Income | 205.38M | (82.31M) | 209.34M | 214.61M | 190.3M |
| Net Margin | 18.9% | -7.3% | 18.6% | 18.9% | 17.5% |
| EPS (Basic) | 4.09 | (1.65) | 4.21 | 4.32 | 3.93 |
| EPS (Diluted) | 4.04 | (1.65) | 4.17 | 4.29 | 3.91 |
| Weighted Avg Shares | 50.26M | 49.88M | 49.76M | 49.7M | 48.46M |
| Weighted Avg Shares (Diluted) | 50.84M | 49.89M | 50.18M | 50.08M | 48.72M |
Prestige Consumer Healthcare Inc.
NYSE:PBH
Intrinsic Alpha fair value
Locked
Current Price
$50.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.